NTI Shares Neurotech International Limited
ASX · ASXLast in our picks 2026-10-24 — not in the current list; analysis below is from that screen
New Phase 3 autism trial creates a material catalyst for its cannabinoid-based paediatric therapy.
Future value: $0.02 (+5.26%) · 6-12 months
Signal breakdown
- ▸Phase 3 Beyond Harmony trial launch increases clinical visibility.
- ▸Above 50-day MA (+32.87%)
- ▸Above 200-day MA — long-term uptrend
- ▸Near 52-week high (81.8% of range) — strength
Is NTI a buy right now?
Trend: NTI is trading above the 50-day average (+80.00%), RSI 47 — neutral momentum, with a 3-month return of +12.50%.
Valuation & quality: fundamentals show net margin -138.1%, return on equity -366.7%.
Our screen: BUY (score 3) — New Phase 3 autism trial creates a material catalyst for its cannabinoid-based paediatric therapy.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +100.00% | -50.00% | +0.00% | +100.00% |
Fundamentals
Technical signals
About Neurotech International Limited
Neurotech International Limited, a clinical-stage biopharmaceutical development company, focuses on development of solutions for paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy in Australia.
Sector: Healthcare · Industry: Biotechnology · Australia · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.